Background {#Sec1}
==========

*Cratoxylum cochinchinense* Blume (Clusiaceae) is a deciduous shrub tree growing abundantly in southeast Asian countries \[[@CR1]\]. The leaves, stems, barks, roots and latex of *C. cochinchinense* have been used as traditional Chinese medicine for the treatment of various diseases such as jaundice, edema, cough, itch, fever, diarrhea, hoarseness, diuretic, flu, colic, ulcer and dental problems and so on \[[@CR2]--[@CR4]\]. In addition, the young leaves have been used as an herbal substitute for tea and the immature fruit as a spice for cooking \[[@CR5]\]. The simple and caged xanthones with significant antineoplastic activity have been reported from previous phytochemical investigations \[[@CR6]--[@CR12]\]. Aiming to identify structural diverse xanthones and search for novel antitumor natural products from the Clusiaceae \[[@CR13]--[@CR18]\], we continued our studies on the petroleum ether-soluble and dichloromethane-soluble portions of the stems and leaves of *C. cochinchinense* which exhibited moderate cytotoxicity against human myeloid leukemia (HL-60), human prostate cancer (PC-3) and human breast carcinoma (MDA-MB-231) cell lines with IC~50~ values of 7.59, 21.49, 19.63 and 7.86, 32.48, 30.40 μg/ml, respectively. A pair of new enantiomers of xanthones, (+)- and (−)-cracochinxanthone A (**1a** and **1b**), as well as thirty known analogues (**2--31**) were obtained (Fig. [1](#Fig1){ref-type="fig"}). In the present paper, the isolation and structure elucidation of new enantiomers of **1a** and **1b**, as well as the biological evaluation of some selected xanthones are presented.Fig. 1Chemical structures of xanthones **1**--**31**

Materials and methods {#Sec2}
=====================

Information of experimental design and resources {#Sec3}
------------------------------------------------

The Minimum Standards of Reporting Checklist contains details of the experimental design, and statistics, and resources used in this study (Additional file [1](#MOESM1){ref-type="media"}).

General experimental procedures {#Sec4}
-------------------------------

^1^H NMR, ^13^C NMR, HSQC, and HMBC were recorded on the Bruker-ARX-400 and Bruker-AV-600 NMR with tetramethylsilane (TMS) as internal standard. HRESIMS spectra were measured on a Bruker micrOTOF-Q mass spectrometer. Optical rotations were measured by the JASCO P-2000 polarimeter. UV spectra were recorded on a Shimadzu UV-2201 spectrometer. ECD spectra were measured on the BioLogic MOS 450 AF/CD at room temperature. Multimode Reader were used by a Varioskan Flash. The semi-preparative HPLC was a Shimadzu SPD-20A series equipped with an YMC C~18~ column (250 × 20 mm, 5 μm, 2 mL/min). Chiral HPLC was a CHIRALPAK IB (250 × 4.6 mm) from Daicel Chiral Technologies Co., Ltd., China. Column chromatography (CC) was conducted on silica gel (100--200 and 200--300 mesh) and preparative and analytical TLC was performed on precoated GF254 plates (Qingdao Haiyang Chemical Co., Ltd., China), octadecyl silane (ODS) (50 µm, YMC Co., Ltd., Kyoto, Japan) and Sephadex LH-20 (GE Healthcare, Uppsala, Sweden). All the organic solvents were purchased from Yuwang and Laibo Chemicals Industries, Ltd., China.

Plant material {#Sec5}
--------------

Stems and leaves of *Cratoxylum cochinchinense* were collected in December 2016, at Mengla County, Xishuangbanna Autonomous Prefecture, People's Republic of China, and were identified by Zhi Na (Kunming Institute of Botany, Chinese Academy of Sciences). The voucher specimen (HNMJY-2016) was deposited in the Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, China.

Extraction and isolation {#Sec6}
------------------------

The smashed leaves and stems of *C. cochinchinense* (10 kg) were macerated with 80% aqueous acetone at room temperature (3 × 80 L, 3 days each time). The combined extracts was suspended in water, and successively partitioned to produce petroleum ether (PE), dichloromethane (CH~2~Cl~2~), ethyl acetate (EtOAc), *n*-butyl alcohol (*n*-BuOH) and water (H~2~O) fractions. The CH~2~Cl~2~ extract (140 g) was fractionated on a silica gel CC and eluted with a PE/EtOAc gradient (100:0, 100:1, 100:3, 100:5, 100:7, 100:10, 100:20, 100:30, 100:50, 0:100) to give ten fractions (Fr. A--J). Fraction D was purified by ODS CC with a stepwise gradient elution using MeOH/H~2~O to afford **23** (154.8 mg), **29** (8.2 mg), **22** (5.8 mg), **26** (8.7 mg) and yield two subfractions D3 and D4. Fr. D3 was subsequently refined over Sephadex LH-20 (MeOH), followed by semi-preparative HPLC using 77% MeOH in H~2~O as a mobile phase to get **19** (15.8 mg, t~R~ = 63.5 min) and **1** (3.2 mg, t~R~ = 93.3 min). Then, **1** was separated by chiral HPLC eluting with *n*-hexane: isopropanol (90:10) to yield **1a** (0.92 mg, t~R~ = 15.4 min) and **1b** (1.1 mg, t~R~ = 18.4 min). Fr. D4 was also chromatographed on Sephadex LH-20 (MeOH) and semi-preparative HPLC (64% MeOH in H~2~O) to produce **6** (4.5 mg, t~R~ = 38.4 min) and **9** (6.5 mg, t~R~ = 40.3 min). Fr. F was fractionated by ODS CC (MeOH/H~2~O) to give **27** (7.5 mg), **18** (5.3 mg), **20** (7.9 mg) and three major subfractions F2, F5 and F8. Fr. F2 was successively partitioned by a Sephadex LH-20 column (MeOH) to provide the key subfraction F2.2. Fr. F2.2 was further processed via semi-preparative HPLC using 56% aqueous MeOH as the mobile phase to afford **3** (10.2 mg, t~R~ = 28.0 min) and **4** (7.8 mg, t~R~ = 32.2 min). Fr. F5 was recrystallized with methanol to yield **19** (50.1 mg). Fr. F8 was loaded onto semi-preparative HPLC using 82% aqueous MeOH to gain **24** (6.9 mg, t~R~ = 87.5 min), **25** (10.2 mg, t~R~ = 92.5 min) and **21** (15.2 mg, t~R~ = 121.5 min). Fr. H was subjected to ODS CC, which afford **15** (6.9 mg) through further recrystallization and subfractions H3 and H5. Fr. H3 and Fr. H5 were applied to Sephadex LH-20 column and eluted with MeOH to obtain **7** (5.4 mg) and **8** (7.5 mg), respectively. Fr. I was subjected to ODS CC to furnish **13** (5.2 mg), **14** (2.8 mg), and subfraction I4. Fr. I4 followed by Sephadex LH-20 CC to afford **28** (11.6 mg). Fr. J was rechromatographed over silica gel CC, affording **12** (4.6 mg), **11** (3.2 mg) and **10** (13.4 mg).

The PE extract (69 g) was chromatographed on a silica gel CC and eluted stepwise with a PE/EtOAc gradient system (100:1, 100:3, 100:7, 100:15, 100:50, 100:100, 0:100) to afford the major fractions A′-G′. Fr. C′ was subjected to separation over ODS CC to yield **30** (8.8 mg) and subfraction C′8. Fr. C′8 was further purified over a silica gel CC and followed by semi-preparative HPLC with 90% aqueous MeOH as mobile phase under isocratic condition to furnish **31** (10.7 mg, t~R~ = 25.5 min). Fr. D′ was separated via ODS CC to provide **2** (15.5 mg), which was crystallized from the 65% MeOH/H~2~O solution, and to give subfraction D′5. Fr. D′5 was chromatographed over Sephadex LH-20 eluting with MeOH to give **17** (6.7 mg). Fr. E′ was initially subjected to ODS CC to yield subfraction E′3 and E′8. Fr. E′3 was further purified by semi-preparative HPLC eluted with 60% MeOH/H~2~O to give **16** (9.3 mg, t~R~ = 35.8 min). Fr. E′8 was again subjected to ODS CC to obtain **5** (3.1 mg).

Cracochinxanthone A **(1)**: yellow needle crystal; UV (MeOH) *λ*~max~ (log ε) 319 (3.86), 268 (4.23), 235 (4.21) nm; ^1^H, ^13^C NMR and HMBC data see Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 379.1541 \[M + H\]^+^ (calcd for C~23~H~23~O~5~, 379.1540).Table 1^1^H (600 MHz), ^13^C NMR (150 MHz) and HMBC data for compound **1** in DMSO-*d*~6~Position^1^H-NMR (*mult, J in Hz*)^13^C--NMRHMBC (^1^H → ^13^C)1158.02108.03163.54106.357.46 (1H, d, *J *= 9.0 Hz)118.6C-7, 8a, 10a67.28 (1H, dd, *J *= 9.0, 3.0 Hz)124.4C-8, 10a7153.887.40 (1H, d, *J *= 3.0 Hz)107.9C-6, 9, 10a9179.94a152.98a120.19a101.510a149.01′2.95 (1H, dd, *J *= 14.7, 3.1 Hz)\
2.82 (1H, dd, *J *= 14.7, 8.0 Hz)28.9C-1, 2, 3, 2′, 3′2′4.24 (1H, dd, *J *= 8.0, 2.3 Hz)74.8C-2, 1′, 3′3′147.14′4.89 and 4.75 (each 1H, s)110.0C-2′, 3′, 5′5′1.76 (3H, s)18.1C-2′, 3′, 4′1″3.43 (2H, d, *J *= 7.2 Hz)21.6C-3, 4, 4a, 2″, 3″2″5.19 (1H, t, *J *= 7.2 Hz)122.5C-1″, 4″, 5″3″130.64″1.82 (3H, s)17.8C-2″, 3″, 5″5″1.62 (3H, s)25.6C-2″, 3″1-OH13.35 (1H, s)C-1, 2, 9a7-OH9.95 (1H, s)C-6, 7, 8

(+) Cracochinxanthone A (**1a**). Yellow needles; $\documentclass[12pt]{minimal}
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                \begin{document}$$\left[ \alpha \right]_{\text{D}}^{25}$$\end{document}$ + 10.0 (*c* 0.06 MeOH); ECD (MeOH 0.58) *λ*~max~ (Δ*ε*) 241 (+ 3.65), 270 (− 4.22), 317 (− 1.91) nm.

(−) Cracochinxanthone A (**1b**). Yellow needles; $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\left[ \alpha \right]_{\text{D}}^{25}$$\end{document}$ − 11.3 (*c* 0.07 MeOH); ECD (MeOH 0.70) *λ*~max~ (Δ*ε*) 242 (− 4.06), 273 (+ 3.72), 316 (+ 1.45) nm.

Anticancer assay in vitro {#Sec7}
-------------------------

The antiproliferative activities of some selected compounds against the HL-60, PC-3, and MDA-MB-231 cancer cell lines were evaluated. 5-Fluorouracil (5-FU) was used as a positive control. Detailed methodology for the cell growth inhibition test has been described in a previous report \[[@CR19]\]. The IC~50~ values were calculated by SPSS 16.0 software and results were repeated three times that were expressed as mean ± SD.

Results {#Sec8}
=======

Cracochinxanthone A (**1**) was obtained as a yellow needle, and its molecular formula was determined as C~23~H~22~O~5~ with 13° of unsaturation from the HRESIMS data of \[M + H\]^+^ ion at *m/z* 379.1541 (calcd for C~23~H~23~O~5~, 379.1540). The UV bands observed at *λ*~max~ 319, 268 and 235 nm suggested a xanthone skeleton \[[@CR13]\]. The ^1^H NMR data showed signals for a hydrogen bond hydroxy proton at *δ*~H~ 13.35 (1H, s, OH-1), a free phenolic hydroxy proton at *δ*~H~ 9.95 (1H, s, OH-7), a set of ABX coupling system aromatic protons at *δ*~H~ 7.40 (1H, d, *J *= 3.0 Hz, H-8), 7.46 (1H, d, *J *= 9.0 Hz, H-5) and 7.28 (1H, dd, *J *= 9.0, 3.0 Hz, H-6), along with the typical signals of a 3-methylbut-2-enyl (prenyl) moiety at *δ*~H~ 3.43 (2H, d, *J *= 7.2 Hz, H-1″), 5.19 (1H, t, *J *= 7.2 Hz, H-2″), 1.82 (3H, s, CH~3~-4″) and 1.62 (3H, s, CH~3~-5″). The remaining proton signals were assigned to a dihydrofuran ring with an isopropenyl group at *δ*~H~ 2.95 (1H, dd, *J *= 14.7, 3.1 Hz, Ha-1′), 2.82 (1H, dd, *J *= 14.7, 8.0 Hz, Hb-1′), 4.24 (1H, dd, *J *= 8.0, 2.3 Hz, H-2′), 4.89 and 4.75 (each 1H, s, Ha-4′, Hb-4′), 1.76 (3H, s, CH~3~-5′), and the corresponding carbon signals at *δ*~C~ 147.1 (C-3′), 110.0 (C-4′), 74.8 (C-2′), 28.9 (C-1′) and 18.1 (C-5′) were assigned through HSQC correlations \[[@CR20]\]. The ^13^C NMR displayed 23 carbon resonances including one conjugated carbonyl carbon, sixteen aromatic/olefinic carbons, three methyl, two methylene and one oxygenated methine (Table [1](#Tab1){ref-type="table"}). The dihydrofuran ring with an isopropenyl group was fused with xanthone skeleton at position C-2 and C-3, based on the HMBC correlations from Ha-1′ (*δ*~H~ 2.95) and Hb-1′ (2.82) to C-1 (*δ*~C~ 158.0), C-2 (108.0) and C-3 (163.5), as well as from H-2′ (*δ*~H~ 4.24) to C-2. The cross peaks between H-1″ (*δ*~H~ 3.43) and C-3, C-4a (*δ*~C~ 152.9) and C-4 (106.3) confirmed the location of the prenyl group at C-4. The correlations of H-5 (*δ*~H~ 7.46) with C-7 (*δ*~C~ 153.8), C-8a (120.1) and C-10a (149.0), H-8 (*δ*~H~ 7.40) with C-6 (124.4), C-9 (*δ*~C~ 179.9) and C-10a, H-6 (*δ*~H~ 7.28) with C-8 (*δ*~C~ 107.9) and C-10a, and OH-7 (*δ* 9.95) with C-6, C-7 and C-8 indicated that the free phenolic hydroxy located at C-7 (Fig. [2](#Fig2){ref-type="fig"}). Based on these results, the structure of **1** was assigned to a new compound, namely cracochinxanthone A.Fig. 2Key HMBC correlations of **1**

Cracochinxanthone A might be a racemic mixture due to the smooth ECD curve as well as close to zero optical rotation. Subsequent chiral HPLC separation of **1** gave the corresponding enantiomers **1a** and **1b** possessing the opposite ECD curves. Their experimental ECD spectra matched well with the calculated ones for *R* and *S*, respectively, thus, explicitly assigning the absolute configurations of **1a** and **1b** (Fig. [3](#Fig3){ref-type="fig"}). And the optical rotations of **1a** and **1b** were + 10.0 (*c* 0.06 MeOH) and − 11.3 (*c* 0.07 MeOH), respectively. Therefore, the structures of **1a** and **1b** were named as (+) and (−)-cracochinxanthone A.Fig. 3Experimental and calculated ECD spectra of **1a** and **1b**

By comparison with those data from the literatures, the known analogues were identified as cochinchinoxanthone (**2**) \[[@CR21]\], 1,4,7-trihydroxy-8-methoxyxanthone (**3**) \[[@CR22]\], gentisein (**4**) \[[@CR23]\], 1,6-dihydroxy-2,5,8-trimethoxyxanthone (**5**) \[[@CR23]\], 1,7-dihydroxyxanthone (**6**) \[[@CR24]\], 1,7-dihydroxy-4-methoxyxanthone (**7**) \[[@CR25]\], 1,7-dihydroxy-3,6-dimethoxyxanthone (**8**) \[[@CR26]\], 1,7-dihydroxy-8-methoxyxanthone (**9**) \[[@CR27]\], 1,5,6-trihydroxy-7-methoxyxanthone (**10**) \[[@CR28]\], 1,4,7-trihydroxyxanthone (**11**) \[[@CR29]\], 1,5,6-trihydroxy-3,7-dimethoxyxanthone (**12**) \[[@CR30]\], 1,3,5,6-tetrahydroxyxanthone (**13**) \[[@CR31]\], 1,3,6,7-tetrahydroxyxanthone (**14**) \[[@CR32]\], 1,3,6-trihydroxy-7-methoxyxanthone (**15**) \[[@CR29]\], cratoxanthone C (**16**) \[[@CR33]\], 1,2,4-trimethoxy-3,8-dimethoxyxanthone (**17**) \[[@CR34]\], 1,3,7-trihydroxy-2-(3-methylbut-2-enyl)-xanthone (**18**) \[[@CR35]\], dulcisxanthone B (**19**) \[[@CR20]\], cudratricusxanthone E (**20**) \[[@CR36]\], γ-mangostin (**21**) \[[@CR37]\], 1,3,7-trihydroxy-2,4-diisoprenylxanthone (**22**) \[[@CR38]\], cochinchinone A (**23**) \[[@CR33]\], cochinchinone B (**24**) \[[@CR33]\], pruniflorone Q (**25**) \[[@CR39]\], 1,3,5-trihydroxy-6′,6′-dimethyl-2*H*-pyrano(2′,3:6,7)xanthone (**26**) \[[@CR30]\], pruniflorone N (**27**) \[[@CR40]\], xanthone V~1~ (**28**) \[[@CR41]\], osajaxanthone (**29**) \[[@CR42]\], cochinchinone I (**30**) \[[@CR43]\], 1,7-dihydroxy-4-(3,7-dimethylocta-2,6-dienyl)-5′-(1-hydroxy-1-methylethyl)-4′,5′-dihydrofuro\[2′,3′:3,2\]-xanthone (**31**) \[[@CR44]\].

Discussions {#Sec9}
===========

The antiproliferative activities of some xanthones were evaluated against HL-60, PC-3, and MDA-MB-231 cancer cell lines (Table [2](#Tab2){ref-type="table"}). The isolates **1a**, **1b**, **3**, **4**, **6**, **10**, **12**, **19**--**25**, **27** and **28** displayed antiproliferative effect against HL-60 cells with IC~50~ values ranging from 1.00 to 19.78 μM, especially **23** bearing one prenyl and one geranyl groups with an IC~50~ value of 1.0 μM and **27** possessing a pyran ring with 1-hydroxy-4,4-dimethyl with an IC~50~ value of 1.89 μM. Compounds **19**--**25**, **27** and **28** exhibited potent inhibitory activity against PC-3 cells with IC~50~ values ranging from 11.77 to 27.11 μM and compounds **1b**, **19**--**25** and **28** displayed significant cytotoxicity against MDA-MB-231 cells with IC~50~ values ranging from 7.94 to 18.46 μM, respectively. It is worth to mention that compounds **23**--**25** possessing one prenyl and one geranyl and **19**--**22** with two prenyl groups showed high sensitivity against three human cancer cell lines than others without prenyl unit.Table 2Cytotoxicities of selected compounds (IC~50~ μM)CompoundsHL-60PC-3MDA-MB-231**1a**12.08 ± 0.84\> 50\> 50**1b**19.24 ± 1.51\> 5018.46 ± 1.65**3**19.78 ± 2.09\> 50\> 50**4**18.00 ± 1.04\> 50\> 50**6**15.56 ± 0.51\> 50\> 50**9**\> 50\> 50\> 50**10**10.43 ± 0.31\> 50\> 50**11**\> 50\> 50\> 50**12**10.77 ± 0.13\> 50\> 50**19**2.62 ± 0.7421.87 ± 1.947.94 ± 0.94**20**4.50 ± 0.1711.77 ± 0.1911.97 ± 0.65**21**3.07 ± 0.1627.11 ± 1.4913.30 ± 1.09**22**9.64 ± 0.3420.60 ± 1.6414.59 ± 1.26**23**1.00 ± 0.2111.95 ± 1.369.40 ± 1.28**24**6.18 ± 0.3114.99 ± 1.2815.96 ± 0.46**25**4.47 ± 0.1414.57 ± 1.2711.55 ± 1.25**27**1.89 ± 0.5422.94 ± 1.97\> 50**28**4.52 ± 0.9720.72 ± 2.0416.37 ± 1.32**5-FU** ^**a**^2.20 ± 0.0825.98 ± 1.0838.69 ± 2.84IC~50~ values expressed as mean ± standard deviation, n = 3^a^Positive control

Conclusions {#Sec10}
===========

A pair of new racemic mixture of xanthones, (+)-cracochinxanthone A (**1a**) and (−)-cracochinxanthone A (**1b**), along with 30 known analogues (**2**--**31**) were isolated from the stems and leaves of *C. cochinchinense.* The antiproliferative activities of some selected compounds against human HL-60, PC-3, and MDA-MB-231 cancer cell lines were screened by the trypan blue and MTT methods. The polyprenylated or geranylated xanthones exhibited potent cytotoxicity against three human malignant cell lines, which could be further developed as potential lead compounds in the design for the treatment of cancer.
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HL-60

:   human myeloid leukemia cell line

PC-3

:   human prostate cancer cell line

MDA-MB-231

:   human breast carcinoma cell line

ODS

:   octadecyl silane

CC

:   column chromatography

TMS

:   tetramethylsilane

PE

:   petroleum ether

CH~2~Cl~2~

:   dichloromethane

EtOAc

:   ethyl acetate

*n*-BuOH

:   *n*-butyl alcohol

H~2~O

:   water

ECD

:   electronic circular dichroic spectroscopy

HPLC

:   high performance liquid chromatography

IC~50~

:   the concentration of drug required to inhibit cell growth by 50% compared with untreated control
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